Unverified
No Broad Autism Approval for Leucovorin, Despite FDA Commissioner’s Prior Suggestions
The claim that no broad autism approval has been granted for leucovorin despite suggestions by the FDA commissioner lacks sufficient evidence.
Key points
- No specific documents or studies are provided to support the claim about leucovorin and autism approval.
- FDA Commissioner's suggestions do not automatically lead to drug approvals.
- Leucovorin is used for various medical conditions, but its use in autism treatment is not widely recognized.
Explanation
The claim states that no broad autism approval has been granted for leucovorin despite suggestions by the FDA commissioner. However, there are insufficient sources to verify this statement. The claim does not provide specific documents or studies to support these assertions. Additionally, it is important to note that an FDA commissioner's suggestion alone does not guarantee drug approval; a rigorous review process must be completed. Leucovorin is commonly used for treating folate deficiency and certain cancers but its application in autism treatment is not widely recognized.